within Pharmacolibrary.Drugs.ATC.D;

model D01AE10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 8.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D01AE10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ethyl hydroxybenzoate, also known as ethylparaben, is a paraben-class preservative with antifungal and antibacterial properties, commonly used in cosmetics, pharmaceuticals, and food products to prevent microbial growth. It is sometimes used topically for dermatological applications due to its antifungal effects (ATC code D01AE10), but is not a primary therapeutic drug and is not approved for systemic use as a medicine.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies in humans are available for ethyl hydroxybenzoate itself. The following parameters are broad estimates based on chemical similarity to other parabens (such as methylparaben and propylparaben) and limited reports of rapid absorption and elimination after oral or topical administration in animal models and indirect human exposure studies.</p><h4>References</h4><ol><li><p>Shin, MY, et al., &amp; Kim, S (2023). Pharmacokinetics of transdermal methyl-, ethyl-, and propylparaben in humans following single dermal administration. <i>Chemosphere</i> 310 136689–None. DOI:<a href=\"https://doi.org/10.1016/j.chemosphere.2022.136689\">10.1016/j.chemosphere.2022.136689</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36220432/\">https://pubmed.ncbi.nlm.nih.gov/36220432</a></p></li><li><p>Gad, HA, et al., &amp; Kamel, AO (2023). Ethyl lauroyl arginate-based hydrophobic ion pair complex in lipid nanocapsules: A novel oral delivery approach of rosmarinic acid for enhanced permeability and bioavailability. <i>International journal of pharmaceutics</i> 630 122388–None. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2022.122388\">10.1016/j.ijpharm.2022.122388</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36375682/\">https://pubmed.ncbi.nlm.nih.gov/36375682</a></p></li><li><p>Moustafine, RI, et al., &amp; Khutoryanskiy, VV (2019). Interpolymer complexes of carbopol® 971 and poly(2-ethyl-2-oxazoline): Physicochemical studies of complexation and formulations for oral drug delivery. <i>International journal of pharmaceutics</i> 558 53–62. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2019.01.002\">10.1016/j.ijpharm.2019.01.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30634031/\">https://pubmed.ncbi.nlm.nih.gov/30634031</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D01AE10;
